BioCentury | Jun 29, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) discontinued development of Graspa eryaspase to treat acute lymphoblastic leukemia (ALL...
...to continue development of Graspa for acute myelogenous leukemia (AML). Erytech reported in December that Graspa...
...acute lymphoblastic leukemia (ALL) Endpoint: NA Status: Development discontinued Milestone: NA Jennie Walters ERY-ASP, Graspa, eryasp, eryaspase (ERY001) Erytech...
BioCentury | Jun 25, 2018
Clinical News

Erytech discontinues Graspa's leukemia program, shifts focus to solid tumors

...S.A. (Euronext:ERYP; NASDAQ:ERYP) shares fell Monday on news that the company discontinued development of Graspa eryaspase...
...to continue development of Graspa for acute myelogenous leukemia (AML). Erytech reported in December that Graspa...
...a Phase II trial in previously untreated pancreatic cancer in 1H19. Jennie Walters ERY-ASP, Graspa, eryasp, eryaspase (ERY001) Erytech...
BioCentury | Dec 14, 2017
Clinical News

Erytech's Graspa misses in Phase IIb AML study

...Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP) reported top-line data showing that Graspa eryaspase (ERY-ASP, ERY001) missed the...
...myelogenous leukemia (AML) in patients ineligible for intensive chemotherapy. On the 123-patient trial's primary endpoint, Graspa...
...in red blood cells. Erytech Pharma S.A. (Euronext:ERYP; NASDAQ:ERYP), Lyon, France Product: Graspa eryaspase (ERY-ASP, ERY001...
BioCentury | Dec 8, 2017
Clinical News

Erytech sinks after Graspa miss in AML study

...S.A. (Euronext:ERYP; NASDAQ:ERYP) lost $8.80 (31%) to $19.20 on NASDAQ Friday after it said Graspa eryaspase...
...The company fell €7.21 (31%) to €16.34 on Euronext. On the 123-patient trial's primary endpoint, Graspa...
...the product to treat ALL and AML. Eryaspase comprises L-asparaginase encapsulated in red blood cells. Chris Lieu eryaspase Graspa Erytech...
BioCentury | Nov 17, 2017
Financial News

Erytech raises $125M, lists on NASDAQ

...see BioCentury, Oct. 13 ). Last month, Erytech resubmitted an MAA to EMA for Graspa eryaspase...
...acute lymphoblastic leukemia (ALL). The company withdrew an MAA for the product in November 2016. Eryaspase...
BioCentury | Nov 15, 2017
Financial News

Erytech raises $125M, lists on NASDAQ

...BioCentury Extra, Oct. 13) . Last month, Erytech resubmitted an MAA to EMA for Graspa eryaspase...
...acute lymphoblastic leukemia (ALL). The company withdrew an MAA for the product in November 2016. Eryaspase...
...exclusive European rights to commercialize the product to treat ALL and acute myelogenous leukemia (AML). Alicia Parker eryaspase Graspa Erytech...
BioCentury | Oct 27, 2017
Clinical News

Erytech reports additional Phase IIb data for eryaspase in pancreatic cancer

...trial to treat progressive metastatic pancreatic cancer showing that second-line treatment with eryaspase (Graspa, ERY-ASP, ERY001...
...Eryaspase comprises L-asparaginase encapsulated in red blood cells. Erytech Pharma S.A. (Euronext:ERYP), Lyon, France Product: Eryaspase...
...encapsulated in red blood cells. Erytech Pharma S.A. (Euronext:ERYP), Lyon, France Product: Eryaspase (Graspa, ERY-ASP, ERY001...
BioCentury | Oct 13, 2017
Financial News

Erytech seeking NASDAQ listing

...the U.S. and Canada. On Oct. 10, Erytech resubmitted an MAA to EMA for Graspa eryaspase...
...MAA in November 2016. By 3Q18, Erytech also plans to start Phase III studies of Graspa...
...in December from a Phase II/III trial of Graspa to treat acute myelogenous leukemia (AML). Graspa...
BioCentury | Oct 9, 2017
Financial News

Erytech seeking NASDAQ listing

...U.S. and Canada. This month, Erytech plans to resubmit an MAA to EMA for Graspa eryaspase...
...MAA in November 2016. By 3Q18, Erytech also plans to start Phase III studies of Graspa...
...in December from a Phase II/III trial of Graspa to treat acute myelogenous leukemia (AML). Graspa...
BioCentury | Jul 8, 2017
Finance

A clinical quarter

...migraine Ph III SPARTAN data 2H17 Erytech Pharma S.A. (Euronext:ERYP) / Recordati S.p.A. (Milan:REC) Graspa eryaspase...
Items per page:
1 - 10 of 54